In our study, we aimed at investigating this polymorphism in relation to the effectiveness of anti-TNF-α biologic treatment in IBD patients evaluated with a strong outcome, such as SFR, thus observing that the presence of a homozygous mutated genotype is a predictive factor for non-achievement of SFR. The gene discussed is TNF; the disease is inflammatory bowel disease.